Lupin's founder handed CEO and MD jobs to his daughter and son in 2013; records followed

In May 2013, Lupin's board appointed Vinita Gupta — daughter of founder and chairman Desh Bandhu Gupta — as chief executive and her brother Nilesh as managing director, effective September 1, 2013. Long-time MD Kamal Sharma moved up to vice-chairman to mentor the pair.

The founder stayed chairman and active until his death in June 2017, but day-to-day leadership was now the children's. Vinita, a pharmacist who had led Lupin's US business, took the growth mandate: the company set a goal of becoming a $5 billion firm by 2018.

The second generation delivered. Lupin's revenue rose from ₹9,462 crore in FY2013 to ₹13,758 crore in FY2016, net profit climbed 72% to ₹2,261 crore, and the US became 45% of sales. A share worth about ₹5 in 2000 hit an all-time high of ₹2,107 in 2015 — more than 400 times.

Revenue rose from ₹9,462 crore (FY2013) to ₹13,758 crore (FY2016), net profit climbed 72% to ₹2,261 crore, and market value had grown 900% since 2000.

Handing over early gave the next generation time to learn while the founder watched.

The US business experience of the new CEO was the right runway for growth.

Keeping a veteran vice-chairman smoothed the transition instead of cutting it.

A founder can delegate before he dies: DB Gupta moved his children into the top jobs while he still chaired, kept a veteran as mentor, and the second generation delivered the company's record years.

The record run hit a wall after 2017, when US FDA import alerts and generics price erosion hit Lupin's largest market. By 2018 the second-generation team was leading a revival, with the company citing its leadership structure as the reason it could react fast.